Lisa Wendt

Join me and Team LUNGevity this year at the Chicago Marathon to combine two of the things I love most: running and helping my lung cancer patients! Donate here: do.nr/16np8n7n via @DonorDrive

CheckMate 77T - phase 3 trial of neoadj chemo-nivolumab followed by adjuvant nivolumab is pos for event-free survival. Results may help delineate contribution of adjuvant PD-1 blockade after neoadjuvant chemo-PD1 when looked at in context of CM816. #lcsm news.bms.com/news/corporate…

🚨Job posting!! 🚨 Come work with our expanding crit care team in Augusta💃 level 1 trauma, ECMO center, precepting opportunities, and more! Message for more info. Link below⬇️

Super super teeeeny tiny, but super cool that we're starting to get some data in these patients

@janthony3PharmD Thanks Josiah!! Congrats to you too!

@lisawendt2 Congratulations!!!

Sappy post incoming but PGY-2 Oncology ✅

@SEngPharmD Thanks Stephen!!

@lisawendt2 Congratulations Lisa!

Ok, Pedro Pascal as chemotherapy/anti-cancer therapy…generic names only! Rituximab

Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵nature.com/articles/s4158…

…and that’s a wrap on #HOPAAC23 🎉🌵🏀

Coresidents, puppies, CE and @OncoPharmPod. A great first day at #HOPAAC23

Very nicely written review article. Will be a valuable resource for learners --> Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review - Kathleen B. Orrico, 2023 journals.sagepub.com/doi/full/10.11…

Me: Trying her best to juggle PGY2, job applications, family Life:

Day 3 #GI23 Highlights #CommunityOncology 1. #MOUNTAINEER: Tucat+Trast approved CRC 2. #SUNLIGHT: TAS102+Bev confirmed late option CRC 3. #E2211: Cape+Tem in pNET manuscript 4. #ctDNA kinetics CRC 5. TNT state in RectalCA @ASCO #OncEd #MedEd @OncoAlert #GISM #MedTwitter

Congrats! @KoheiShitara & #GastricCancer world #SPOTLIGHT P3 (+) trial for Zolbetuximab + FOLFOX vs. FOLFOX in mG/GEJ adenoca. (mostly PD-L1 CPS<5%) PFS HR 0.75 🔥 mOS 18.2 vs 15.5 HR 0.75👇🏼Other ongoing CLDN18.2 targeting trials for #PancreaticCancer @MSKCancerCenter @CpcrMsk

📢🥁By popular demand presenting the TOP Oncology publications of 2022. PS: List not exhaustive - so feel free to tag & add important papers to the list @OncoAlert @NEJM @TheLancetOncol @Annals_Oncology @NatureMedicine @Nature @CD_AACR

It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022: Some negative, some positive, but we learned from all! Feel free to add more & retweet & tag anyone involved This is not an exhaustive list! @OncoAlert @danafarber #OnwardFor2023

Had the amazing opportunity to give a lecture on prostate cancer at Rutgers University COP today ☺️

Interested in a PGY2 oncology residency? You’re invited (and we’re excited) to share our program offerings during live information sessions! Please use the QR code below to confirm your attendance. We look forward to meeting you and answering any questions you may have! 🎉

LISTEN HERE FOLKS it’s that time of year again!! 🙌🏼🙌🏼 We will be hosting our virtual open houses!!! Please scan the QR code to sign up and hear all about what our amazing residency program has to offer!! 💉🤩👏🏼